IDEAYA Biosciences, Inc. announced on December 10, 2024, that it has dosed the first patient in its Phase 1 trial evaluating IDE161 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The trial focuses on endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable (MSS).
IDE161 is a potential first-in-class inhibitor of poly(ADP-ribose) glycohydrolase (PARG), a novel target in the same biological pathway as PARP. The program has already received two FDA Fast Track designations for other indications.
This trial is part of IDEAYA's broader IDE161 clinical combination strategy, focusing on high-conviction rational combinations. Under the collaboration, Merck will provide KEYTRUDA to IDEAYA, the study sponsor, with both companies retaining commercial rights to their respective compounds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.